Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

XBIO Xenetic Biosciences, Inc.
$1.49 -10.24% -0.17
Notify me if price changes either direction
Interactive Brokers Logotype

Buy XBIO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Xenetic Biosciences, Inc. (XBIO)

Loading

Key Stats

Market cap. 3.5M
Enterprise value -2582085
Trailing PE -0.94303798071946
Forward PE -2.5151513
PEG Ratio 0.10609177283094
Enterprise to EBITDA 0.91092266866861
Enterprise to revenue -0.792
Price to book MRQ 0.51440966
Price to sales TTM 1.1928691

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 3.3M
Diluted EPS TTM -1.15
Total Cash (MRQ) 6.5M
Current ratio (MRQ) 7.435
Operating Cash Flow (TTM) -2312795

XBIO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent XBIO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.